Valuation: Kamada Ltd.

Market Cap 1.3B 130B 433M 379M 348M 324M 615M 41.25B 624M 4.18B 1.62B 20.26B 1.63B 1.59B 69.91B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 1.3B 130B 433M 379M 348M 324M 615M 41.25B 624M 4.18B 1.62B 20.26B 1.63B 1.59B 69.91B EV / Sales 2026 *
2.22x
EV / Sales 2027 * 2.02x
Free-Float
54.51%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 57 01/07/2015
Director of Finance/CFO 55 31/12/2017
Chief Operating Officer 53 01/11/2016
Director TitleAgeSince
Director/Board Member 75 13/12/1990
Chairman 77 07/03/2013
Chairman 55 12/08/2020
Change 5-day change 1-year change 3-year change Capi.($)
-0.53%-1.04% - - 435M
+4.73%+5.50%+19.45%-8.94% 66.56B
-1.93%+1.13%+55.67%+219.58% 57.64B
+1.07%+42.10%+42.10%+42.10% 42.24B
+3.45%+3.54%-49.20%-56.09% 39.09B
+3.04%+7.01%+62.26%-24.13% 31.91B
+10.01%+33.49%+163.41%-34.35% 31.65B
+2.68%+8.68%+71.42%+87.73% 23.35B
+2.87%+15.37%+10.72%+196.62% 18.92B
-0.13%+1.91%+67.83%+127.66% 17.17B
Average +2.53%+7.39%+49.30%+61.13% 36.5B
Weighted average by Cap. +2.77%+6.50%+44.29%+54.03%

Financials

2026 *2027 *
Net sales 585M 58.47B 195M 171M 157M 146M 277M 18.58B 281M 1.88B 732M 9.13B 733M 717M 31.5B 642M 64.19B 214M 187M 172M 160M 304M 20.4B 309M 2.07B 803M 10.02B 805M 787M 34.57B
Net income 72.01M 7.2B 24.04M 21.03M 19.3M 17.98M 34.1M 2.29B 34.64M 232M 90.12M 1.12B 90.26M 88.3M 3.88B 104M 10.36B 34.6M 30.26M 27.77M 25.88M 49.07M 3.29B 49.86M 334M 130M 1.62B 130M 127M 5.58B
Net Debt - -
Logo Kamada Ltd.
Kamada Ltd is Israel based company, focused on plasma-derived protein therapeutics with a commercial product portfolio and a late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins.
Employees
-
Trader
-
Investor
-
Global
-
Quality
ESG MSCI
-